NO930201L - Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk - Google Patents

Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk

Info

Publication number
NO930201L
NO930201L NO93930201A NO930201A NO930201L NO 930201 L NO930201 L NO 930201L NO 93930201 A NO93930201 A NO 93930201A NO 930201 A NO930201 A NO 930201A NO 930201 L NO930201 L NO 930201L
Authority
NO
Norway
Prior art keywords
selective
preparation
leukotrien
antagonist activity
substituted bicyclic
Prior art date
Application number
NO93930201A
Other languages
English (en)
Other versions
NO930201D0 (no
Inventor
Norbert Dereu
Wolfram Hendel
Richard Labaudiniere
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO930201D0 publication Critical patent/NO930201D0/no
Publication of NO930201L publication Critical patent/NO930201L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med selektive UBegenskaper med formel (I):. omfattende en aryl- eller heteroaryl mono- eller blcyklisk ring som har minst to substituenter bundet til seg; (1) en substituert eller usubstituert aryl- eller heteroaryl mono- eller blcyklisk ring og (2) en substltuent-kjede med terminale karboksylsyrefunksjonell gruppe eller derivater derav bundet dertil.Fremgangsmåter for fremstilling av forbindelsene beskrives.Forbindelsene egner seg for behandling av mangler som Involverer LTB-agonlstmedlert aktivitet.
NO93930201A 1990-07-24 1993-01-21 Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk NO930201L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9009453A FR2665159B1 (fr) 1990-07-24 1990-07-24 Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
PCT/EP1991/001341 WO1992001675A2 (en) 1990-07-24 1991-07-18 Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NO930201D0 NO930201D0 (no) 1993-01-21
NO930201L true NO930201L (no) 1993-01-21

Family

ID=9399053

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930201A NO930201L (no) 1990-07-24 1993-01-21 Substituerte bicykliske bis-arylforbindelser med selektivleukotrien-b4-antagonistaktivitet, deres fremstilling og bruk

Country Status (15)

Country Link
US (2) US5366982A (no)
EP (1) EP0540604A1 (no)
JP (1) JPH05508845A (no)
AU (1) AU8194891A (no)
CA (1) CA2087848A1 (no)
CZ (1) CZ403192A3 (no)
FI (1) FI930256A0 (no)
FR (1) FR2665159B1 (no)
HU (1) HUT68663A (no)
IE (1) IE912589A1 (no)
IL (1) IL98921A0 (no)
NO (1) NO930201L (no)
PT (1) PT98438A (no)
WO (1) WO1992001675A2 (no)
ZA (1) ZA915759B (no)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
FR2705959B1 (fr) * 1993-06-01 1995-08-11 Oreal Procédé de synthèse stéréospécifique de leucotriène B4 sous sa configuration 6Z, 8E, 10E et produits intermédiaires.
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
WO1995028386A1 (en) * 1994-04-13 1995-10-26 F. Hoffmann-La Roche Ag Substituted pyridine leukotriene b4 antagonists
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
US6103465A (en) * 1995-02-14 2000-08-15 The Perkin-Elmer Corporation Methods and reagents for typing HLA class I genes
US5571825A (en) * 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
ES2243978T3 (es) * 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
EP0999856B1 (en) * 1996-10-07 2003-05-14 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
WO1998042346A1 (en) * 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6812237B2 (en) 2000-05-15 2004-11-02 Novartis Ag N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
US6696466B1 (en) 2000-09-07 2004-02-24 Leslie Joe Dunaway Methods of treating select neuronal inflammatory disorders using hydroxyalkylquinolines
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
AU2002247402A1 (en) * 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
TWI316055B (no) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
KR100888408B1 (ko) 2001-07-13 2009-03-13 아스트라제네카 유케이 리미티드 아미노피리미딘 화합물의 제조 방법
DE60305446T4 (de) * 2002-01-07 2009-07-09 Eisai R&D Management Co., Ltd. Desazapurine und deren verwendung
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
US6921752B2 (en) * 2002-03-26 2005-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of LTB4 antagonists in veterinary medicine
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003275242B2 (en) * 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
DE60330050D1 (de) 2002-12-16 2009-12-24 Astrazeneca Uk Ltd Verfahren zur herstellung von pyrimidinverbindungen
AU2004228011A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
WO2004094379A2 (en) * 2003-04-16 2004-11-04 Amgen Inc. 3-phenyl-4- (pyrimidin-2-yl) -6- (piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations
RU2356896C2 (ru) 2003-04-16 2009-05-27 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
JP2007510652A (ja) * 2003-11-03 2007-04-26 サイトキネティクス・インコーポレーテッド ピリミジン−４−オン化合物、組成物、および方法
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
EP1692112A4 (en) * 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
WO2005097137A2 (en) * 2004-03-31 2005-10-20 The Scripps Research Institute Advanced quinazoline based protein kinase inhibitors
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20070026503A (ko) * 2004-05-14 2007-03-08 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물
WO2005115148A1 (en) * 2004-05-24 2005-12-08 Cropsolution, Inc. 3-aryl-3-hydroxy-2-methylenepropionic acid esters as fungicides
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
DE102005044156A1 (de) * 2005-09-15 2007-03-29 Riemser Arzneimittel Ag Substituierte Acetophenonderivate
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
IN266803B (no) 2005-12-22 2015-06-03 Newron Pharm Spa
DE102006021872B4 (de) * 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2662852A1 (en) * 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
US8093253B2 (en) 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
CA2728311A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
WO2010006944A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Aminotetrahydroindazoloacetic acids
JP5302398B2 (ja) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー 置換アミノテトラリン
CN102149677A (zh) 2008-08-15 2011-08-10 霍夫曼-拉罗奇有限公司 联芳基氨基四氢化萘类
RS52809B (sr) 2008-11-17 2013-10-31 F. Hoffmann-La Roche Ag. Naftilsirćetne kiseline
KR20110071122A (ko) 2008-11-17 2011-06-28 에프. 호프만-라 로슈 아게 나프틸아세트산
JP5373104B2 (ja) 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
ES2587232T3 (es) 2010-07-20 2016-10-21 Vestaron Corporation Triazinas y pirimidinas insecticidas
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
PT3013796T (pt) 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
MX385777B (es) * 2014-12-24 2025-03-04 Lg Chemical Ltd Derivado de biarilo como agonista de gpr120.
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
EP3350146A4 (en) * 2015-09-14 2019-03-06 The Regents of The University of California PREPARATION OF FURANT FATURES FROM 5- (CHLOROMETHYL) FURFURAL
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11731946B2 (en) 2017-10-19 2023-08-22 The General Hospital Corporation Broad spectrum antivirulence, anti-persistence compounds
US20230210837A1 (en) * 2021-12-31 2023-07-06 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN116874433A (zh) * 2023-06-16 2023-10-13 上海应用技术大学 一种嘧啶类化合物及其合成方法及应用
CN118745145A (zh) * 2024-06-24 2024-10-08 湖南大学 一类2-羟基吡啶类衍生物及其合成方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE667498A (no) * 1964-07-28 1965-11-16
JPS5758666A (en) * 1980-09-24 1982-04-08 Otsuka Pharmaceut Co Ltd Alkanoic acid derivative
DE3211395A1 (de) * 1982-03-27 1983-09-29 Hoechst Ag, 6230 Frankfurt Pyridon-2-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
WO1987005510A1 (en) * 1986-03-13 1987-09-24 Rorer International (Overseas) Inc. Quinolinyl ether or thioether tetrazoles as agents for the treatment of hypersensitive ailments
CA1315279C (en) * 1987-01-12 1993-03-30 Nancy Grace Bollinger Anti-inflammatory agents
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
US5004743A (en) * 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds

Also Published As

Publication number Publication date
FI930256L (fi) 1993-01-22
US5492915A (en) 1996-02-20
HUT68663A (en) 1995-07-28
FR2665159A1 (fr) 1992-01-31
FI930256A7 (fi) 1993-01-22
ZA915759B (en) 1992-05-27
PT98438A (pt) 1992-05-29
FR2665159B1 (fr) 1992-11-13
EP0540604A1 (en) 1993-05-12
NO930201D0 (no) 1993-01-21
WO1992001675A2 (en) 1992-02-06
HU9300190D0 (en) 1993-04-28
WO1992001675A3 (en) 1992-08-06
AU8194891A (en) 1992-02-18
JPH05508845A (ja) 1993-12-09
CZ403192A3 (en) 1993-09-15
FI930256A0 (fi) 1993-01-22
IE912589A1 (en) 1992-01-29
IL98921A0 (en) 1992-07-15
US5366982A (en) 1994-11-22
CA2087848A1 (en) 1992-01-25

Similar Documents

Publication Publication Date Title
WO1992001675A3 (en) Substituted bicyclic bis-aryl compounds exhibiting selective leukotriene b4 antagonist activity, their preparation and use in pharmaceutical compositions
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
NO900306D0 (no) Fremgangsmaate for fremstilling av nye pyrazolopyridin-forbindelser.
BG101422A (bg) Бензоксазолни производни като бронхоразширяващи средства
NO874454D0 (no) Nye derivater av benzimidazoler med anti-ulcusaktivitet og fremgangsmaate for deres fremstilling.
ATE910T1 (de) Derivate des 3.5-dihydroxypentansaeureesters mit antihyperlipaemischer aktivitaet, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES474229A1 (es) Un procedimiento de preparacion de derivados de fenil-4-ami-no-2-tiazol
CA2114727A1 (en) Quinoline Derivatives as Immunostimulants
DK506587A (da) Imidderivater
MX9300222A (es) Nuevos derivados de arilcicloalquilo, su preparacion y su utilizacion.
DE3665711D1 (de) Novel guanidinomethylbenzoic acid derivatives
ATE13178T1 (de) 2-oxoazetidin-derivate, ihre herstellung und verwendung.
ATE39357T1 (de) Derivate von griseolicsaeure und ihre verwendung.
DE3782347D1 (de) Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel.
GB1531963A (en) Pyrido(1,2alpha)pyrimidine derivatives
NO961236L (no) Pyrrolodiazin-derivater som stabilisatorer for klorholdige polymerisater
IE40052B1 (en) Indole derivatives
GB1517960A (en) Furanhydroxamic acid derivatives useful as fungicides
GB1158868A (en) Novel 2,4-Disubstituted 7- and 8-Chloroquinolines, the preparation thereof and Compositions containing the same
DE3668888D1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.
IE32678B1 (en) Novel thiazoline derivatives,the preparation thereof and compositions containing the same
GB1498535A (en) Heterocyclic compounds
IE43614L (en) Diphenylamines.
GB1447827A (en) Benzimidazole derivatives
MX9204642A (es) 1,4-dihidropiridinas con actividad paf-antagonista